2,5-二溴己二酸 | 3479-85-4

• 物质功能分类: 有机原料 - 羧酸类化合物及衍生物
• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 中文名称: 2,5-二溴己二酸
• 英文名称: α.α'-Dibrom-adipinsaeure
• 英文别名: rac-α,α'-Dibrom-adipinsaeure；2,5-Dibromoadipic acid；2,5-dibromohexanedioic acid
• CAS: 3479-85-4
• 化学式: C₆H₈Br₂O₄
• mdl: MFCD00046516
• 分子量: 303.935
• InChiKey: KABAKEOYQZKPBA-UHFFFAOYSA-N

物化性质

• 熔点：
  188°C
• 沸点：
  395.4±42.0 °C(Predicted)
• 密度：
  2.111±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  12
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.666
• 拓扑面积：
  74.6
• 氢给体数：
  2
• 氢受体数：
  4

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi
• 海关编码：
  2917190090
• 包装等级：
  II
• 危险类别：
  8
• 危险性防范说明：
  P260,P264,P270,P271,P280,P301+P312,P301+P330+P331,P303+P361+P353,P304+P340,P305+P351+P338,P310,P321,P363,P403+P233,P405,P501
• 危险品运输编号：
  3261
• 危险性描述：
  H302,H314,H335

SDS

---

SECTION 1: Identification of the substance/mixture and of the company/undertaking
Product identifiers
Product name : 2,5-DIBROMOADIPIC ACID
REACH No. : A registration number is not available for this substance as the substance
or its uses are exempted from registration, the annual tonnage does not
require a registration or the registration is envisaged for a later
registration deadline.
CAS-No. : 3479-85-4
Relevant identified uses of the substance or mixture and uses advised against
Identified uses : Laboratory chemicals, Manufacture of substances

---

SECTION 2: Hazards identification
Classification of the substance or mixture
Classification according to Regulation (EC) No 1272/2008
Acute toxicity, Oral (Category 4), H302
Skin corrosion (Category 1B), H314
Specific target organ toxicity - single exposure (Category 3), H335
Serious eye damage (Category 1), H318
For the full text of the H-Statements mentioned in this Section, see Section 16.
Classification according to EU Directives 67/548/EEC or 1999/45/EC
C Corrosive R22, R34
For the full text of the R-phrases mentioned in this Section, see Section 16.
Label elements
Labelling according Regulation (EC) No 1272/2008
Pictogram
Signal word Danger
Hazard statement(s)
H302 Harmful if swallowed.
H314 Causes severe skin burns and eye damage.
H335 May cause respiratory irritation.
Precautionary statement(s)
P261 Avoid breathing dust/ fume/ gas/ mist/ vapours/ spray.
P280 Wear protective gloves/ protective clothing/ eye protection/ face
protection.
P305 + P351 + P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove
contact lenses, if present and easy to do. Continue rinsing.
P310 Immediately call a POISON CENTER or doctor/ physician.
Supplemental Hazard none
Statements
Other hazards - none

---

SECTION 3: Composition/information on ingredients
Substances
Formula : C6H8Br2O4
Molecular Weight : 303,94 g/mol
CAS-No. : 3479-85-4
Hazardous ingredients according to Regulation (EC) No 1272/2008
Component Classification Concentration
2,5-DIBROMOADIPIC ACID
Acute Tox. 4; Skin Corr. 1B; -
STOT SE 3; Eye Dam. 1;
H302, H314, H335
For the full text of the H-Statements and R-Phrases mentioned in this Section, see Section 16

---

SECTION 4: First aid measures
Description of first aid measures
General advice
Consult a physician. Show this safety data sheet to the doctor in attendance.
If inhaled
If breathed in, move person into fresh air. If not breathing, give artificial respiration. Consult a physician.
In case of skin contact
Take off contaminated clothing and shoes immediately. Wash off with soap and plenty of water. Consult a
physician.
In case of eye contact
Rinse thoroughly with plenty of water for at least 15 minutes and consult a physician.
If swallowed
Do NOT induce vomiting. Never give anything by mouth to an unconscious person. Rinse mouth with
water. Consult a physician.
Most important symptoms and effects, both acute and delayed
The most important known symptoms and effects are described in the labelling (see section 2.2) and/or in
section 11
Indication of any immediate medical attention and special treatment needed
no data available

---

SECTION 5: Firefighting measures
Extinguishing media
Suitable extinguishing media
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.
Special hazards arising from the substance or mixture
Carbon oxides, Hydrogen bromide gas
Advice for firefighters
Wear self contained breathing apparatus for fire fighting if necessary.
Further information
no data available

---

SECTION 6: Accidental release measures
Personal precautions, protective equipment and emergency procedures
Use personal protective equipment. Avoid dust formation. Avoid breathing vapours, mist or gas. Ensure
adequate ventilation. Evacuate personnel to safe areas. Avoid breathing dust.
For personal protection see section 8.
Environmental precautions
Do not let product enter drains.
Methods and materials for containment and cleaning up
Pick up and arrange disposal without creating dust. Sweep up and shovel. Keep in suitable, closed
containers for disposal.
Reference to other sections
For disposal see section 13.

---

SECTION 7: Handling and storage
Precautions for safe handling
Avoid contact with skin and eyes. Avoid formation of dust and aerosols.
Provide appropriate exhaust ventilation at places where dust is formed.
For precautions see section 2.2.
Conditions for safe storage, including any incompatibilities
Store in cool place. Keep container tightly closed in a dry and well-ventilated place.
Specific end use(s)
A part from the uses mentioned in section 1.2 no other specific uses are stipulated

---

SECTION 8: Exposure controls/personal protection
Control parameters
Components with workplace control parameters
Exposure controls
Appropriate engineering controls
Handle in accordance with good industrial hygiene and safety practice. Wash hands before breaks and
at the end of workday.
Personal protective equipment
Eye/face protection
Face shield and safety glasses Use equipment for eye protection tested and approved under
appropriate government standards such as NIOSH (US) or EN 166(EU).
Skin protection
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique
(without touching glove's outer surface) to avoid skin contact with this product. Dispose of
contaminated gloves after use in accordance with applicable laws and good laboratory practices.
Wash and dry hands.
The selected protective gloves have to satisfy the specifications of EU Directive 89/686/EEC and
the standard EN 374 derived from it.
Body Protection
Complete suit protecting against chemicals, The type of protective equipment must be selected
according to the concentration and amount of the dangerous substance at the specific workplace.
Respiratory protection
Where risk assessment shows air-purifying respirators are appropriate use a full-face particle
respirator type N100 (US) or type P3 (EN 143) respirator cartridges as a backup to engineering
controls. If the respirator is the sole means of protection, use a full-face supplied air respirator. Use
respirators and components tested and approved under appropriate government standards such
as NIOSH (US) or CEN (EU).
Control of environmental exposure
Do not let product enter drains.

---

SECTION 9: Physical and chemical properties
Information on basic physical and chemical properties
a) Appearance Form: solid
b) Odour no data available
c) Odour Threshold no data available
d) pH no data available
e) Melting point/freezing no data available
point
f) Initial boiling point and no data available
boiling range
g) Flash point no data available
h) Evapouration rate no data available
i) Flammability (solid, gas) no data available
j) Upper/lower no data available
flammability or
explosive limits
k) Vapour pressure no data available
l) Vapour density no data available
m) Relative density no data available
n) Water solubility no data available
o) Partition coefficient: n- log Pow: 1,237
octanol/water
p) Auto-ignition no data available
temperature
q) Decomposition no data available
temperature
r) Viscosity no data available
s) Explosive properties no data available
t) Oxidizing properties no data available
Other safety information
no data available

---

SECTION 10: Stability and reactivity
Reactivity
no data available
Chemical stability
Stable under recommended storage conditions.
Possibility of hazardous reactions
no data available
Conditions to avoid
no data available
Incompatible materials
Strong oxidizing agents
Hazardous decomposition products
Other decomposition products - no data available
In the event of fire: see section 5

---

SECTION 11: Toxicological information
Information on toxicological effects
Acute toxicity
no data available
Skin corrosion/irritation
no data available
Serious eye damage/eye irritation
no data available
Respiratory or skin sensitisation
no data available
Germ cell mutagenicity
Carcinogenicity
IARC: No component of this product present at levels greater than or equal to 0.1% is identified as
probable, possible or confirmed human carcinogen by IARC.
Reproductive toxicity
Specific target organ toxicity - single exposure
May cause respiratory irritation.
Specific target organ toxicity - repeated exposure
no data available
Aspiration hazard
no data available
Additional Information
RTECS: Not available
To the best of our knowledge, the chemical, physical, and toxicological properties have not been
thoroughly investigated., Lachrymation

---

SECTION 12: Ecological information
Toxicity
no data available
Persistence and degradability
no data available
Bioaccumulative potential
no data available
Mobility in soil
no data available
Results of PBT and vPvB assessment
PBT/vPvB assessment not available as chemical safety assessment not required/not conducted
Other adverse effects
no data available

---

SECTION 13: Disposal considerations
Waste treatment methods
Product
Offer surplus and non-recyclable solutions to a licensed disposal company. Dissolve or mix the material
with a combustible solvent and burn in a chemical incinerator equipped with an afterburner and scrubber.
Contaminated packaging
Dispose of as unused product.

---

SECTION 14: Transport information
UN number
ADR/RID: 3261 IMDG: 3261 IATA: 3261
UN proper shipping name
ADR/RID: CORROSIVE SOLID, ACIDIC, ORGANIC, N.O.S. (2,5-DIBROMOADIPIC ACID)
IMDG: CORROSIVE SOLID, ACIDIC, ORGANIC, N.O.S. (2,5-DIBROMOADIPIC ACID)
IATA: Corrosive solid, acidic, organic, n.o.s. (2,5-DIBROMOADIPIC ACID)
Transport hazard class(es)
ADR/RID: 8 IMDG: 8 IATA: 8
Packaging group
ADR/RID: II IMDG: II IATA: II
Environmental hazards
ADR/RID: no IMDG Marine pollutant: no IATA: no
Special precautions for user
no data available

---

---

SECTION 15 - REGULATORY INFORMATION
N/A

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2,5-二溴己二酸 在 氢氧化钾 作用下， 生成 四氢呋喃-2,5-二羧酸
  参考文献：
  名称：

  Le Sueur; Haas, Journal of the Chemical Society, 1910, vol. 97, p. 181

  摘要：

  DOI：
• 作为产物：
  描述：

  己二酰氯 在 N-溴代丁二酰亚胺(NBS) 、 水 、 氢溴酸 作用下， 生成 2,5-二溴己二酸
  参考文献：
  名称：

  Studies toward cyclic trisulfides. Trisulfide polymers and sulfur extrusion

  摘要：

  DOI：

  10.1021/jo00323a019
• 作为试剂：
  描述：

  在 3,3,3-膦三基三丙酸 、 2,5-二溴己二酸 、 碳酸氢铵 、 三氟乙酸 作用下， 以 水 、 乙腈 为溶剂， 反应 5.0h， 生成
  参考文献：
  名称：

  Synthesis and Bioactivity of Diastereomers of the Virulence Lanthipeptide Cytolysin

  摘要：

  Cytolysin, a two-component lanthipeptide comprising cytolysin S (CylL(s)") and cytolysin L (CyILL"), is the only family member to exhibit lytic activity against mammalian cells in addition to synergistic antimicrobial activity. A subset of the thioether cross-links of CylLs" and CylL(L)," have LL stereochemistry instead of the canonical DL stereochemistry in all previously characterized lanthipeptides. The synthesis of a CylLs" variant with DL stereochemistry is reported. Its antimicrobial activity was found to be decreased, but not its lytic activity against red blood cells. Hence, the unusual LL stereochemistry is not responsible for the lytic activity.

  DOI：

  10.1021/acs.orglett.6b03246

文献信息

• A facile synthesis of optically active C2-symmetric 2,5-disubstituted pyrrolidines and other β,β′-dihydroxyamines
  作者：Kevin Koh、Robert N. Ben、T. Durst

  DOI：10.1016/0040-4039(94)85057-7

  日期：1994.1

  has been converted into the di-(R)-pantolactone ester of (S,S)-pyyrolidine-2,5-dicarboxylic acid in two steps. This compound serves as a precursor to C2-symmetric 2,5-disubstituted pyrrolidines. The synthesis of linear C2-symmetric β,β′-dihydroxyamines starting with α-bromophenylacetic acid and (S)-phenylglycine ethyl ester is also reported.

  2，5-二溴己二酸已分两步转化为（S，S）-吡咯烷-2,5-二羧酸的二-（R）-泛内酯。该化合物用作C 2对称的2，5-二取代的吡咯烷的前体。还报道了以α-溴苯基乙酸和（S）-苯基甘氨酸乙酯为起始原料的线性C 2对称β，β'-二羟基胺的合成。
• [EN] DICYANOPYRROLIDINES AS DIPEPTIDYL PEPTIDASE IV INHIBITORS<br/>[FR] DICYANOPYRROLIDINES INHIBITEURS DE LA DIPEPTIDYL PEPTIDASE IV
  申请人：PFIZER PROD INC

  公开号：WO2005095339A1

  公开（公告）日：2005-10-13

  The invention provides compounds of formula (I), the prodrugs and stereoisomers thereof, and the pharmaceutically acceptable salts of the compounds, prodrugs, and stereoisomers, wherein wherein R is as defined herein; pharmaceutical compositions thereof; combinations thereof; and uses thereof in the treatment of diabetic complications including diabetic neuropathy, diabetic nephropathy, diabetic microangiopathy, and the like.

  该发明提供了如下式（I）的化合物，其前药和立体异构体，以及该化合物、前药和立体异构体的药用可接受盐，其中R如本文所定义；其药物组合物；其组合物；以及在治疗糖尿病并发症包括糖尿病神经病变、糖尿病肾病、糖尿病微血管病变等方面的用途。
• Azabicycloalkane derivatives and therapeutic uses thereof
  申请人：——

  公开号：US20020052355A1

  公开（公告）日：2002-05-02

  The present invention is directed to a compound of the formula (I): 1 and pharmaceutically acceptable salts thereof, wherein R 1 , R 2 , Y, U, W, k, A, E, V, R 4 and R 5 are as defined herein, pharmaceutical compositions thereof, and methods of use thereof in the inhibition of serotonin reuptake, the inhibition of the binding of 5-HT 2A serotonin receptors and the treatment of diseases, conditions or disorders of the central nervous system. Further, the present invention is also directed to methods for the preparation of compounds of formula (I) and intermediates useful therefor.

  本发明涉及一种化合物，其化学式为(I):1及其药学上可接受的盐，其中R1、R2、Y、U、W、k、A、E、V、R4和R5如本文所定义，以及其药物组成物，以及在抑制5-羟色胺再摄取、抑制5-HT2A受体结合和治疗中枢神经系统疾病、症状或障碍中的使用方法。此外，本发明还涉及化合物(I)的制备方法和相关中间体的方法。
• Polychelants as contrast enhancing agents
  申请人：Nycomed Salutar Inc.

  公开号：US05958373A1

  公开（公告）日：1999-09-28

  The present invention provides a polychelant compound of formula (VII), (wherein each X which may be the same or different is NZ, O or S, at least two Xs being NZ; B is (CR.sup.1 Y) or --N(CR.sup.1.sub.2 Y)--; each Z is a group R.sup.1 or a group CR.sup.1.sub.2 Y, at least one Z being a group CR.sup.1.sub.2 Y; each Y is a group CO.sub.2 H, PO.sub.3 H, SO.sub.3 H, CONR.sup.1.sub.2, CON(OR.sup.1)R.sup.1, CNS or CONR.sup.1 NR.sup.1.sub.2 ; m is 0 or 1 or 2; each n is 2 or 3; q is 0 or 1 when B is (CR.sup.1 Y) and 2 when B is N(CR.sup.1.sub.2 Y); p is an integer having a value of at least 2; each R.sup.1 which may be the same or different is a hydrogen atom or an alkyl, aryl or aralkyl group optionally substituted by one or more hydroxy or alkoxy groups, or two R.sup.1 groups on ring atoms or in Z groups together represent a linker group L; each L which may be the same or different represents a bond or an organic linker group having a molecular weight of less than 1000 and salts and chelates thereof. These compounds, especially the diand trichelates with paramagnetic or heavy metal ions are especially useful as diagnostic imaging contrast agents.

  本发明提供了一种多螯合物化合物，其化学式为（VII），（其中每个X可能相同或不同，为NZ、O或S，至少两个X为NZ；B为（CR^1Y）或-N(CR^1_2Y)-；每个Z为基团R^1或基团CR^1_2Y，至少一个Z为基团CR^1_2Y；每个Y为基团CO_2H、PO_3H、SO_3H、CONR^1_2、CON(OR^1)R^1、CNS或CONR^1NR^1_2；m为0或1或2；每个n为2或3；当B为（CR^1Y）时，q为0或1，当B为N(CR^1_2Y)时，q为2；p为至少为2的整数；每个R^1可能相同或不同，为氢原子或一个或多个羟基或烷氧基取代的烷基、芳基或芳基烷基，或者环原子上的两个R^1基团或Z基团一起代表一个连接基团L；每个L可能相同或不同，代表一个键或具有分子量小于1000的有机连接基团，以及它们的盐和螯合物。这些化合物，尤其是与顺磁性或重金属离子形成的二和三螯合物，特别适用于作为诊断成像对比剂。
• Azabicycloalkane derivatives for use as serotonin reuptake inhibitors and 5ht2a antagonists
  申请人：Pfizer Products Inc.

  公开号：EP1178048A1

  公开（公告）日：2002-02-06

  The present invention is directed to a compound of the formula (I): and pharmaceutically acceptable salts thereof, wherein R1, R2, Y, U, W, k, A, E, V, R4 and R5 are as defined herein, pharmaceutical compositions thereof, and methods of use thereof in the inhibition of serotonin reuptake, the inhibition of the binding of 5-HT2A serotonin receptors and the treatment of diseases, conditions or disorders of the central nervous system. Further, the present invention is also directed to methods for the preparation of compounds of formula (I) and intermediates useful therefor.

  本发明涉及一种式（I）化合物： 及其药学上可接受的盐，其中 R1、R2、Y、U、W、k、A、E、V、R4 和 R5 如本文所定义；其药物组合物；及其在抑制血清素再摄取、抑制 5-HT2A 血清素受体的结合和治疗中枢神经系统疾病、病症或紊乱中的使用方法。此外，本发明还涉及式（I）化合物及其有用中间体的制备方法。

表征谱图